@article{TCR30190,
author = {Xia Wu and Shihong Ying and Jing Huang and Changsheng Shi and Jiansong Ji and Zhiyi Peng and Guanhui Zhou and Zhichao Sun and Junhui Sun and Wenqiang Yu and Wenhao Hu and Xin Zhang and Jian Zhou and Guoliang Shao and Zhihai Yu and Qinming Hou and Wenjiang Gu and Tiefeng Li and Xiaoxi Xie and Guohong Cao and Haijun Du and Dedong Zhu and Huanhai Xu and Jun Han and Wenbin Ji and Jian Fang and Ling Li and Jiaping Zheng and Jun Luo and Yutang Chen and Tingyang Hu and Hongjie Hu and Xiaohua Guo},
title = {Efficacy and safety of CalliSpheres ® drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study},
journal = {Translational Cancer Research},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: This study aimed to assess the treatment response, short-term overall survival (OS) and safety profiles of drug-eluting beads transarterial chemoembolization (DEB-TACE) in patients with secondary liver cancer.
Methods: Fifty-five patients with secondary liver cancer underwent DEB-TACE were enrolled in this prospective cohort study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST). OS was calculated from the time of DEB-TACE operation until the date of death.
Results: The complete response (CR) and objective response rate (ORR) at 1–3 months post DEB-TACE were 12.7% and 67.3 %. Mean OS was 383 d (95% CI: 360–406), and 6-month OS rate was 93.4%±3.7%. Subgroup analysis revealed previous conventional TACE (cTACE) treatment was correlated with worse ORR (P=0.028), and it was a risk factor for ORR achievement (P=0.021). As for liver function, the percentages of abnormal TP (P=0.031), TBIL (P=0.022), ALT (P=0.002) and AST (P=0.035) were increased at 1 week post DEB-TACE compared to baseline, while these four indexes returned to baseline (all P>0.05) at 1–3 months post DEB-TACE. As to safety profiles, 41 (66.1%), 28 (45.2%), 17 (27.4%), 8 (12.9%) and 6 (9.7%) cases had pain, vomiting, fever, nausea and other adverse events (AEs) respectively during DEB-TACE operation, while 26 (41.9%), 9 (14.5%), 8 (12.9%), 4 (6.5%), 1 (1.6%) and 2 (3.2%) cases had pain, fever, vomiting, nausea, bone marrow toxicity and other AEs respectively at 1 month after DEB-TACE operation.
Conclusions: DEB-TACE was efficient and well tolerated in treating patients with secondary liver cancer.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/30190}
}